Armata Pharmaceuticals, Inc. (ARMP)
| Previous close | 4.6300 |
| Open | 4.6000 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 1800 |
| Day's range | 4.2500 - 4.6100 |
| 52-week range | 2.8200 - 6.4900 |
| Volume | |
| Avg. volume | 10,034 |
| Market cap | 116.742M |
| Beta (5Y monthly) | 0.00 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.0720 |
| Earnings date | 16 Mar 2022 - 21 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.67 |
- PR Newswire
Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter 2022 and provided a corporate update.
- PR Newswire
Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that, following a vote in favor of the transaction by the Armata shareholders, the Company has completed the closing of the second and final tranche of the Company's $45 million private placement of its common stock with Innoviva Strategic Opportunities
- Zacks
Wall Street Analysts See a 52% Upside in Armata Pharmaceuticals, Inc. (ARMP): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 52.5% in Armata Pharmaceuticals, Inc. (ARMP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
